The Effectiveness of Metformin in Managing Second Generation Antipsychotic–Induced Weight Gain in Children and Adolescents

The Journal of
Clinical Psychiatry

Child and Adolescent Psychiatry Weight

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Author Affiliations

Department of Pharmaceutical Health Outcome and Policy, College of Pharmacy, University of Houston, Houston, Texas
Corresponding Author: Hua Chen, MD, PhD, Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, 4849 Calhoun Road, Room 4049, Houston, TX 77204-5047 ([email protected]).
Department of Pharmaceutical Health Outcome and Policy, College of Pharmacy, University of Houston, Houston, Texas
Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, Texas
Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, Texas
Department of Biostatistics and Data Science, School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas

References (21)

Dayabandara M, Hanwella R, Ratnatunga S, et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–2241. PubMed CrossRef
Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6(1):47–53. PubMed CrossRef
Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072–2079. PubMed CrossRef
Arman S, Sadramely MR, Nadi M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J. 2008;29(8):1130–1134. PubMed
Anagnostou E, Aman MG, Handen BL, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(9):928–937. PubMed CrossRef
Correll CU, Sikich L, Reeves G, et al. Metformin add-on vs antipsychotic switch vs continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry. 2020;19(1):69–80. PubMed CrossRef
de Silva VA, Suraweera C, Ratnatunga SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341. PubMed CrossRef
Doyle DL, Sood R. IQVIA. A Diagnostic Framework to Evaluate Real-World Data Sources for Real-World Evidence Generation. 2018. https://www.iqvia.com/-/media/iqvia/pdfs/isporbarcelona2018posters/november-12/a-diagnostic-framework-to-evaluate-real-world-data-sources-for-real-world-evidence-generation.pdf. Accessed July 5, 2023.
Zhou Z, Rahme E, Abrahamowicz M, et al. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol. 2005;162(10):1016–1023. PubMed CrossRef
Desai RJ, Mahesri M, Abdia Y, et al. Association of osteoporosis medication use after hip fracture with prevention of subsequent nonvertebral fractures: an instrumental variable analysis. JAMA Netw Open. 2018;1(3):e180826. PubMed CrossRef
About Child & Teen BMI | Healthy Weight, Nutrition, and Physical Activity | CDC. CDC. Accessed July 31, 2022. https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html
Growth Charts - Clinical Growth Charts. CDC. Accessed July 31, 2022. https://www.cdc.gov/growthcharts/clinical_charts.htm
Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385–1403. PubMed CrossRef
Patel A, Chan W, Aparasu RR, et al. Effect of psychopharmacotherapy on body mass index among children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol. 2017;27(4):349–358. PubMed CrossRef
Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225–233. PubMed CrossRef
Cleveland WS. LOWESS: A program for smoothing scatterplots by robust locally weighted regression. Am Stat. 1981;35(1):54. CrossRef
NIST. LOESS (aka LOWESS). NIST/SEMATECH e-Handbook of Statistical Methods. Accessed July 31, 2022. https://www.itl.nist.gov/div898/handbook/pmd/section1/pmd144.htm
Naumova EN, Must A, Laird NM. Tutorial in Biostatistics: Evaluating the impact of ‘critical periods’ in longitudinal studies of growth using piecewise mixed effects models. Int J Epidemiol. 2001;30(6):1332–1341. PubMed CrossRef
Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. 2012. Accessed July 5, 2023. https://books.google.com/books?hl=en&lr=&id=0exUN1yFBHEC&oi=fnd&pg=PR17&ots=BeqVV_sK1I&sig=MuhoJklAsRxv0BOPg4ufPREUrA8
Calarge CA, Nicol G, Xie D, et al. Correlates of weight gain during long-term risperidone treatment in children and adolescents. Child Adolesc Psychiatry Ment Health. 2012;6(1):21. PubMed CrossRef
Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–1773. PubMed CrossRef